Key result
OPUS digoxin assay avoids DLIS interference compared to ~40% incidence with the TDxII assay.
Why the study?
How do the Abbott TDxII, Baxter Stratus, and Behring OPUS digoxin assays compare in accuracy, precision, and susceptibility to digoxin-like immunoreactive substances?
Population
Serum samples including weighed-in controls, patient samples, neonatal cord blood, pregnant patients, liver…
Comparison
Abbott TDxII, Baxter Stratus, and Behring OPUS… vs Comparison among the three assays
Design
Other
Authors
Loading...
May warrant assay-specific caution in digoxin TDM for DLIS-prone patients; leaves open prospective outcome validation.
Observational
How do the Abbott TDxII, Baxter Stratus, and Behring OPUS digoxin assays compare in accuracy, precision, and susceptibility to digoxin-like immunoreactive substances?
The Behring OPUS assay and ultrafiltered TDxII are preferred for measuring digoxin levels in patients with potential digoxin-like immunoreactive substances or those treated with Digibind.
Dodds et al. (1995) conducted an observational in Digoxin monitoring. Abbott TDxII, Baxter Stratus, and Behring OPUS assays was evaluated on Accuracy, precision, and detection of digoxin-like immunoreactive substances (DLIS). The OPUS assay exhibited no digoxin-like immunoreactive substances interference, whereas the TDxII assay had the highest incidence (40.4% in neonatal cord blood).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: